Jun 01, 2020
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Jan 13, 2020
AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
Dec 23, 2019
CTT Pharmaceuticals provides Corporate Update
Oct 08, 2019
Aurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers
Aug 15, 2019
AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium
Mar 11, 2019
AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
Feb 18, 2019
WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery
Jan 31, 2019
Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
Jan 25, 2019
Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen
Nov 29, 2018
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
Nov 26, 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Nov 07, 2018
AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
Aug 23, 2018
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
Aug 20, 2018
AcelRx Pharmaceuticals to Present at the 2018 Military Health System Research Symposium
May 24, 2018
AcelRx announces FDA acceptance of NDA for DSUVIA
May 09, 2018
AcelRx resubmits New Drug Application for DSUVIA(TM)
May 09, 2018
Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)
May 08, 2018
Oral Proteins and Peptides Market (3rd Edition), 2018-2030
Apr 25, 2018
AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018
Apr 18, 2018
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting